Another randomized, double-blind, placebo-controlled trial involving 354 EGFR mutation-positive advanced lung adenocarcinoma patients showed that the combination of herbal medicine and EGFR-TKI treatment significantly improved median progression-free survival (PFS) compared to EGFR-TKI monotherapy (11). Here, EGFR is linked to lung adenocarcinoma.